[Source: Journal of Antimicrobial Chemotherapy, full page: (LINK). Abstract, edited.]
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin
Wonhee So, James Shurko, Ralph Galega, Rod Quilitz, John N Greene, Grace C Lee
Journal of Antimicrobial Chemotherapy, dky393, https://doi.org/10.1093/jac/dky393
Published: 08 October 2018
We read the article by Fraile-Ribot et al.1 with great interest and herein report another case of ceftolozane/tazobactam-resistant Pseudomonas aeruginosabacteraemia that developed after 5 weeks of exposure to ceftolozane/tazobactam. A retrospective review of the medical records of a single patient case does not mandate review by the University of South Florida College of Medicine Institutional Review Board (IRB), thus informed consent was not required.
… The patient had AML and was induced with cladribine, cytarabine, filgrastim plus mitoxantrone on days 1–6 then reinduced with 5 days of cladribine plus cytarabine on days 15–19. The patient had a long history of hidradenitis…
Topic: pseudomonas aeruginosa – neutropenia – tobramycin – tazobactam – ceftolozane
Issue Section: Research letter
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: email@example.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Keywords: Antibiotics; Drugs Resistance; Pseudomonas aeruginosa; Ceftolozane; Tazobactam; Tobramycin.